Literature DB >> 172853

Seroepidemiologic survey of varicella: Value of specific fluorescent antibody test.

A A Gershon, S Krugman.   

Abstract

The sensitive varicella-zoster fluorescent antibody to membrane antigen (V-Z FAMA) test was used in a seroepidemiologic survey of two outbreaks of varicella involving 30 children. The attack rate of varicella based on clinical observations alone was 60%. The attack rate based on clinical and serological observations lay between 78% and 82%, after excluding those children who had detectable antibody at the time of exposure. No subclinical varicella infection was observed in this small series of patients. No boost in antibody response was observed in immunes who were exposed to varicella. No patients with detectable V-Z antibody by FAMA at the time of exposure developed clinical varicella. The V-Z FAMA test provided helpful information about the immune status of persons exposed to varicella.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 172853

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  13 in total

1.  Cellular and humoral immune responses to varicella-zoster virus in immunocompromised patients during and after varicella-zoster infections.

Authors:  A A Gershon; S P Steinberg
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

2.  Cell-mediated immunity to varicella-zoster virus measured by virus inactivation: mechanism and blocking of the reaction by specific antibody.

Authors:  A A Gershon; S P Steinberg
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

3.  Antibody to varicella-zoster virus after passive immunization against chickenpox.

Authors:  A A Gershon; S Piomelli; M Karpatkin; E Smithwick; S Steinberg
Journal:  J Clin Microbiol       Date:  1978-12       Impact factor: 5.948

4.  Varicella-zoster plaque assay and plaque reduction neutralization test by the immunoperoxidase technique.

Authors:  G Gerna; R W Chambers
Journal:  J Clin Microbiol       Date:  1976-11       Impact factor: 5.948

5.  Comparison of fluorescent-antibody-to-membrane-antigen test, indirect immunofluorescence assay, and a commercial enzyme-linked immunosorbent assay for determination of antibody to varicella-zoster virus.

Authors:  M L Landry; S D Cohen; D R Mayo; C K Fong; W A Andiman
Journal:  J Clin Microbiol       Date:  1987-05       Impact factor: 5.948

6.  Specific immunoglobulin responses after varicella and herpes zoster.

Authors:  J E Cradock-Watson; M K Ridehalgh; M S Bourne
Journal:  J Hyg (Lond)       Date:  1979-04

7.  Nosocomial varicella. Part II: suggested guidelines for management.

Authors:  G F Hayden; J D Meyers; R E Dixon
Journal:  West J Med       Date:  1979-04

8.  Primary vaccine failure after 1 dose of varicella vaccine in healthy children.

Authors:  David E Michalik; Sharon P Steinberg; Philip S Larussa; Kathryn M Edwards; Peter F Wright; Ann M Arvin; Haley A Gans; Anne A Gershon
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

9.  Cell-mediated immunity to varicella-zoster virus demonstrated by viral inactivation with human leukocytes.

Authors:  A A Gershon; S Steinberg; M Smith
Journal:  Infect Immun       Date:  1976-06       Impact factor: 3.441

Review 10.  Recognition and treatment of shingles.

Authors:  A F Nikkels; G E Piérard
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.